TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Immix Biopharma
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Immix Biopharma successfully closed a $100 million public offering of common stock and pre-funded warrants, raising approximately $93.7 million with support from leading biotechnology institutional investors and mutual funds.

Insights
MAIN   positive

Offers unique monthly dividend policy, has never suspended or reduced payments, increased dividends over 130% since IPO, and provides debt and equity capital to smaller private companies


IMMX   positive

Successfully raised significant capital ($93.7M) to support ongoing research and development of their lead CAR-T therapy NXC-201 for AL Amyloidosis